Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.59
APRI's Cash to Debt is ranked lower than
64% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. APRI: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
APRI' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 2.10 Max: No Debt
Current: 0.59
Equity to Asset -0.82
APRI's Equity to Asset is ranked lower than
99% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. APRI: -0.82 )
Ranked among companies with meaningful Equity to Asset only.
APRI' s Equity to Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.45 Max: 0.87
Current: -0.82
-0.82
0.87
F-Score: 1
Z-Score: -53.87
M-Score: -5.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -848.09
APRI's Operating margin (%) is ranked lower than
95% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. APRI: -848.09 )
Ranked among companies with meaningful Operating margin (%) only.
APRI' s Operating margin (%) Range Over the Past 10 Years
Min: -739.13  Med: -436.83 Max: -86.86
Current: -848.09
-739.13
-86.86
Net-margin (%) -825.33
APRI's Net-margin (%) is ranked lower than
95% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. APRI: -825.33 )
Ranked among companies with meaningful Net-margin (%) only.
APRI' s Net-margin (%) Range Over the Past 10 Years
Min: -1077.44  Med: -517.57 Max: -86.81
Current: -825.33
-1077.44
-86.81
ROE (%) -3840.30
APRI's ROE (%) is ranked lower than
100% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. APRI: -3840.30 )
Ranked among companies with meaningful ROE (%) only.
APRI' s ROE (%) Range Over the Past 10 Years
Min: -1512.53  Med: -248.02 Max: -107.76
Current: -3840.3
-1512.53
-107.76
ROA (%) -225.83
APRI's ROA (%) is ranked lower than
98% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. APRI: -225.83 )
Ranked among companies with meaningful ROA (%) only.
APRI' s ROA (%) Range Over the Past 10 Years
Min: -217.31  Med: -97.02 Max: -48.36
Current: -225.83
-217.31
-48.36
ROC (Joel Greenblatt) (%) -2550.47
APRI's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. APRI: -2550.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APRI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2232.26  Med: -264.74 Max: -67.95
Current: -2550.47
-2232.26
-67.95
Revenue Growth (3Y)(%) 4.80
APRI's Revenue Growth (3Y)(%) is ranked lower than
53% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. APRI: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APRI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.80 Max: 105.1
Current: 4.8
0
105.1
EBITDA Growth (3Y)(%) -12.80
APRI's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. APRI: -12.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APRI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.2  Med: -15.60 Max: 49.9
Current: -12.8
-41.2
49.9
EPS Growth (3Y)(%) -14.10
APRI's EPS Growth (3Y)(%) is ranked lower than
73% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. APRI: -14.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APRI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.3  Med: -14.40 Max: 78.2
Current: -14.1
-44.3
78.2
» APRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

APRI Guru Trades in Q4 2014

Jim Simons 53,629 sh (New)
» More
Q1 2015

APRI Guru Trades in Q1 2015

Charles Brandes 53,500 sh (New)
Jim Simons Sold Out
» More
Q2 2015

APRI Guru Trades in Q2 2015

Charles Brandes 53,500 sh (unchged)
» More
Q3 2015

APRI Guru Trades in Q3 2015

Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with APRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 13.75
APRI's P/S is ranked lower than
98% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. APRI: 13.75 )
Ranked among companies with meaningful P/S only.
APRI' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 14.38 Max: 1380
Current: 13.75
0.77
1380
Current Ratio 1.19
APRI's Current Ratio is ranked lower than
82% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. APRI: 1.19 )
Ranked among companies with meaningful Current Ratio only.
APRI' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 2.34 Max: 85.68
Current: 1.19
0.12
85.68
Quick Ratio 1.17
APRI's Quick Ratio is ranked lower than
65% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. APRI: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
APRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 2.31 Max: 85.68
Current: 1.17
0.12
85.68
Days Inventory 80.29
APRI's Days Inventory is ranked higher than
71% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. APRI: 80.29 )
Ranked among companies with meaningful Days Inventory only.
APRI' s Days Inventory Range Over the Past 10 Years
Min: 23.31  Med: 72.39 Max: 121.47
Current: 80.29
23.31
121.47
Days Sales Outstanding 50.98
APRI's Days Sales Outstanding is ranked higher than
71% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. APRI: 50.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
APRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.87  Med: 28.34 Max: 88.55
Current: 50.98
1.87
88.55
Days Payable 122.55
APRI's Days Payable is ranked higher than
74% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. APRI: 122.55 )
Ranked among companies with meaningful Days Payable only.
APRI' s Days Payable Range Over the Past 10 Years
Min: 128.46  Med: 183.84 Max: 341.94
Current: 122.55
128.46
341.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.89
APRI's Price/Median PS Value is ranked higher than
86% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. APRI: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
APRI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 1.23 Max: 165.7
Current: 0.89
0.1
165.7
Price/Graham Number 0.71
APRI's Price/Graham Number is ranked higher than
90% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. APRI: 0.71 )
Ranked among companies with meaningful Price/Graham Number only.
APRI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.33  Med: 0.90 Max: 4
Current: 0.71
0.33
4
Earnings Yield (Greenblatt) (%) -54.64
APRI's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. APRI: -54.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APRI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -80.82  Med: 0.00 Max: 0
Current: -54.64
-80.82
0

More Statistics

Revenue(Mil) $4
EPS $ -0.73
Beta0.50
Short Percentage of Float7.34%
52-Week Range $0.78 - 2.75
Shares Outstanding(Mil)50.41

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 4 10 9
EPS($) -0.45 -0.32 -0.30
EPS without NRI($) -0.45 -0.32 -0.30

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:NXEN.Germany,
Apricus Biosciences Inc was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with our NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.
» More Articles for APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference Feb 02 2016
APRICUS BIOSCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 13 2016
Apricus Biosciences Announces $10 Million Registered Direct Offering Jan 13 2016
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments... Jan 13 2016
Apricus Biosciences Announces $10 Million Registered Direct Offering Jan 13 2016
Apricus Biosciences Announces Year-End 2015 Update and 2016 Growth Strategy Jan 06 2016
Apricus Biosciences Announces Year-End 2015 Update and 2016 Growth Strategy Jan 06 2016
Apricus Biosciences, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 16 2015
APRICUS BIOSCIENCES, INC. Financials Dec 08 2015
Repros Hits 52-Week Low after Enclomiphene Receives CRL Dec 02 2015
Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary... Dec 01 2015
Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary... Dec 01 2015
Apricus Biosciences Named to Deloitte's 2015 Technology Fast 500(TM) List of Fastest Growing... Nov 17 2015
Apricus Biosciences Named to Deloitte's 2015 Technology Fast 500(TM) List of Fastest Growing... Nov 17 2015
Apricus Biosciences to Present at the Stifel 2015 Healthcare Conference Nov 12 2015
Apricus Biosciences to Present at the Stifel 2015 Healthcare Conference Nov 12 2015
Edited Transcript of APRI earnings conference call or presentation 5-Nov-15 10:00pm GMT Nov 09 2015
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure Nov 06 2015
Apricus reports 3Q loss Nov 05 2015
Apricus reports 3Q loss Nov 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK